Y-mAbs Therapeutics, Inc. (YMAB)
NASDAQ: YMAB · Real-Time Price · USD
8.28
-0.29 (-3.38%)
Dec 20, 2024, 4:00 PM EST - Market closed
Y-mAbs Therapeutics Revenue
Y-mAbs Therapeutics had revenue of $18.46M in the quarter ending September 30, 2024, a decrease of -9.74%. This brings the company's revenue in the last twelve months to $84.55M, down -8.99% year-over-year. In the year 2023, Y-mAbs Therapeutics had annual revenue of $84.82M with 29.96% growth.
Revenue (ttm)
$84.55M
Revenue Growth
-8.99%
P/S Ratio
4.31
Revenue / Employee
$845,530
Employees
100
Market Cap
370.85M
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Enhabit | 1.04B |
ZimVie | 451.29M |
Quanterix | 129.33M |
Personalis | 87.49M |
REGENXBIO | 84.33M |
Alpha Teknova | 36.35M |
Nano-X Imaging | 10.68M |
Taysha Gene Therapies | 9.92M |
YMAB News
- 14 days ago - Y-mAbs Presents SADA Platform Preclinical Data and Trial in Progress Posters at the 2024 American Society Hematology (ASH) Annual Meeting - GlobeNewsWire
- 24 days ago - Y-mAbs to Participate at Citi's 2024 Global Healthcare Conference - GlobeNewsWire
- 6 weeks ago - Y-mAbs Therapeutics, Inc. (YMAB) Q3 2024 Earnings Call Transcript - Seeking Alpha
- 6 weeks ago - Y-mAbs Reports Third Quarter 2024 Financial Results and Recent Corporate Developments - GlobeNewsWire
- 6 weeks ago - Y-mAbs and Nobelpharma Announce Exclusive License and Distribution Agreement for DANYELZA® (naxitamab-gqgk) in Japan - GlobeNewsWire
- 2 months ago - Y-mAbs Announces Third Quarter 2024 Conference Call and Webcast - GlobeNewsWire
- 2 months ago - Y-mAbs to Participate in Upcoming Investor Conferences in October - GlobeNewsWire
- 3 months ago - Y-mAbs Presents Neuroblastoma Research on Naxitamab and SADA PRIT Technology Platform at AACR Special Conference on Advances in Pediatric Cancer Research - GlobeNewsWire